BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
BioNexus Gene Lab enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
BioNexus Gene Lab's enterprise value was $843.57K on Nov 11, 2026, against $7.00M a year earlier. Over the last 5 years it ranged from $843.57K to $43.76B, with a median of $81.73M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $843.57K | -85.8% |
| 2025 | Dec 31, 2025 | $5.94M | -87.1% |
| 2024 | Dec 31, 2024 | $46.12M | -47.7% |
| 2023 | Dec 29, 2023 | $88.15M | -99.6% |
| 2022 | Dec 30, 2022 | $19.80B | -54.7% |
| 2021 | Dec 31, 2021 | $43.76B | +54.4% |
| 2020 | Dec 31, 2020 | $28.35B | – |
See a number that looks wrong?